Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infections, Pediatrics
Conditions
Infections, Pediatrics
Trial Timeline
Dec 1, 2011 → Jul 1, 2014
NCT ID
NCT01400867About Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid is a phase 2/3 stage product being developed by AstraZeneca for Infections, Pediatrics. The current trial status is completed. This product is registered under clinical trial identifier NCT01400867. Target conditions include Infections, Pediatrics.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01400867 | Phase 2/3 | Completed |
Competing Products
20 competing products in Infections, Pediatrics